Case 1:13-cv-03675-WBH Document 108-4 Filed 12/30/16 Page 558 of 586

Exhibit 13

Brandon Stamper_

From:	Mahmoud A. ElSohly, Ph.D. [elsohly@elsohly.com]
Sent:	Wednesday, June 01, 2011 10:34 AM
To:	'Amy Eichner, Ph.D.'
Cc:	'Larry D. Bowers, Ph.D.'; 'Dr. Ikhlas Kahn'; 'Waseem Gul'
Subject:	RE: numbers for Jack3d distribution??

Hi Amy,

In the next couple of days we will conclude all our testing and will have a very clear picture. Anyway, it appears that the levels are really low (in the parts per billion range). Let's wait and see the final outcome by the most sensitive method.

Warmest regards, Mahmoud A. ElSohly, Ph.D., BCFE, BCFM President PSI (Phytochemical Services, Incorporated) 5 Industrial Park Drive Oxford, MS 38655 Tel (662) 236-2609 Fax (662) 234-0253

From: Amy Eichner, Ph.D. [mailto:AEichner@usada.org]
Sent: Monday, May 30, 2011 5:47 PM
To: Mahmoud A. ElSohly, Ph.D.
Cc: Larry D. Bowers, Ph.D.; 'Dr. Ikhlas Kahn'; 'Waseem Gul'
Subject: RE: numbers for Jack3d distribution??

Hi Mahmoud- Just got back into town and internet access.

From this point, sample authentication will be important. The commercially available "geranium oil" may be from a variety of sources. Was DMP found in the extracted sample?

If it is in there at a measurable level, then our message will obviously change slightly. We will focus more heavily on synthetic DMP NOT being a dietary ingredient, but DMP extracted from a plant meets the definition of a dietary ingredient.

Interesting

Λmy

From: Mahmoud A. ElSohly, Ph.D. [elsohly@elsohly.com] Sent: Friday, May 27, 2011 3:33 PM To: Amy Eichner, Ph.D. Cc: Larry D. Bowers, Ph.D.; 'Dr. Ikhlas Kahn'; 'Waseem Gul' Subject: RE: numbers for Jack3d distribution??

Dear Amy,

I left you a message on your voice mail to call me. Since you didn't, I am responding to your email.

Case 1:13-cv-03675-WBH Document 108-4 Filed 12/30/16 Page 560 of 586

As I told you we were going to also develop LC/MS/MS, we have actually started and just got the first set of data right before getting your email. The LC/MS/MS method is 1000 times more sensitive than the GC/MS method. We analyzed the samples you just sent to me by the LC/MS/MS method and they do contain low levels of DMP (in the ng/mL range). Therefore, we are going back and will analyze all samples, that were analyzed earlier by the GC/MS method, by the LC/MS/MS methods. Our final report will contain data by both methods.

Please call when you can.

Thanks,

Mahmoud A. ElSohly, Ph.D., BCFE, BCFM

President

PSI (Phytochemical Services, Incorporated)

5 Industrial Park Drive

Oxford, MS 38655

Tel (662) 236-2609

Fax (662) 234-0253

From: Amy Eichner, Ph.D. [mailto:AEichner@usada.org] Sent: Friday, May 27, 2011 9:44 AM To: Ikhlas A. Khan Cc: elsohly@elsohly.com Subject: FW: numbers for Jack3d distribution??

Hi Ikhlas and Mahmoud-

Keep your ears to the ground on this. It seems that some folks from AHPA (Devon and maybe Steven Dentali?) are pushing that a lab has found methylhex in geranium oil. Anyway you can get some information on this rumour?

I think we're going to have to really lobby the FDA to rule on this once and for all, and your reputation might be a critical factor here. I don't want the trade associations writing the rules here.

Also, I wanted to float this past you- I'd like to see if we can get an editorial published in a high profile journal-like Science or JAMA or BMA or something- discussing the importance and implications of our paper. Do you think Mark Blumenthal would be a good person to write the editorial and try to get it in somewhere big? From what I can see, the authors of the original paper are not usually the authors of an editorial. What do you think? Would he be a useful person to bring in on this story as well?

Best,

Amy

From: Wyszumiala, Edward [ewyszumail@nsf.org] Sent: Friday, May 27, 2011 8:32 AM To: Amy Eichner, Ph.D.; Bestervelt, Lori Subject: RE: numbers for Jack3d distribution??

Devon told me, but Stephen was there as well, he said it wasn't confirmed yet, but Devon was pushing it as the truth. They wouldn't divulge the lab, I was keen on getting this info and what there methodology was?.

Could be good insight into where they are going with this?

From: Amy Eichner, Ph.D. [mailto:AEichner@usada.org] Sent: Friday, May 27, 2011 9:42 AM To: Wyszumiala, Edward; Bestervelt, Lori Subject: RE: numbers for Jack3d distribution??

You are kidding me? Who did they say it was? Was it Steven Dentali that told you?

If you say something enough, lies become the truth.

At any rate, our paper is going to be expedited- I hope it's out in the next two months. It seems like it takes forever. We're going to work hard on the FDA to rule on this once and for all.

Amy

From: Wyszumiala, Edward [ewyszumail@nsf.org] Sent: Friday, May 27, 2011 7:28 AM To: Amy Eichner, Ph.D.: Bestervelt, Lori Subject: RE: numbers for Jack3d distribution??

Hi Amy.

I don't have any exact data on this. The NBJ didn't have any data on them based on the last sport nutrition edition they sent out back in Feb.

Its exciting to hear this work is getting done soon! FYI – AHPA mentioned to me that they talked with a lab that tested geranium and found methylhexanamine in it? Haven't seen the data or know what lab and plant they used, maybe just industry spin.

Talk with you soon, Ed

From: Amy Eichner, Ph.D. [mailto:AEichner@usada.org] Sent: Monday, May 23, 2011 5:46 PM To: Bestervelt, Lori; Wyszumiala, Edward Subject: numbers for Jack3d distribution??

Hey guys- Do you have any number estimates for how many bottles of Jack3d have sold so far? I know it was a GNC top seller, so maybe there are some numbers published in a business journal or something?

We're going to be publishing the geranium oil stuff with Ikhlas very soon- looks like J Forensic Toxicology- they are going to expedite the paper. Should be submitted in 1-2 weeks- not sure how long it takes to review and publish but the editor promised a quick turn around given the story.

Amy

CONFIDENTIALITY NOTICE - This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain information that is confidential or legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of any of the information contained in or attached to this transmission is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify the sender by telephone or return e-mail and delete the original transmission and its attachments without reading or saving in any manner. Thank you.

NOTICE: This email and its contents/attachments may be confidential and are intended solely for the individual to whom it is addressed.

If you are not the named addressee or if this email is otherwise received in error, please immediately notify the sender without reading it and do not take any action based on its contents or otherwise copy or disclose it to anyone. Any opinions or views expressed in

this transmission are solely of the author and do not necessarily represent those of NSF International or its affiliates.

CONFIDENTIALITY NOTICE - This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain information that is confidential or legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of any of the information contained in or attached to this transmission is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify the sender by telephone or return e-mail and delete the original transmission and its attachments without reading or saving in any manner. Thank you.

NOTICE: This email and its contents/attachments may be confidential and are intended solely for the individual to whom it is addressed.

If you are not the named addressee or if this email is otherwise received in error, please immediately notify the sender without reading it and do not take any action based on its contents or otherwise copy or disclose it to anyone. Any opinions or views

expressed in

this transmission are solely of the author and do not necessarily represent those of NSF International or its affiliates.

CONFIDENTIALITY NOTICE - This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain information that is confidential or legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of any of the information contained in or attached to this transmission is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify the sender by telephone or return e-mail and delete the original transmission and its attachments without reading or saving in any manner. Thank you.

CONFIDENTIALITY NOTICE - This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain information that is confidential or legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of any of the information contained in or attached to this transmission is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify the sender by telephone or return e-mail and delete the original transmission and its attachments without reading or saving in any manner. Thank you.